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Alginate coated chitosan nanoparticles were previously developed with the aim of protecting the antigen, adsorbed on the surface of
those chitosan nanoparticles, from enzymatic degradation at mucosal surfaces. In this work, this new delivery system was loaded with the
recombinant hepatitis B surface antigen (HBsAg) and applied to mice by the intranasal route. Adjuvant effect of the delivery system was
studied by measuring anti-HBsAg IgG in serum, anti-HBsAg sIgA in faeces extracts or nasal and vaginal secretions and interferon-c
production in supernatants of the spleen cells. The mice were primed with 10 lg of the vaccine associated or not with nanoparticles
and associated or not with 10 lg CpG oligodeoxynucleotide (ODN) followed by two sequential boosts at three week intervals. The asso-
ciation of HBsAg with the alginate coated chitosan nanoparticles, administered intranasally to the mice, gave rise to the humoral muco-
sal immune response. Humoral systemic immune response was not induced by the HBsAg loaded nanoparticles alone. The generation of
Th1-biased antigen-specific systemic antibodies, however, was observed when HBsAg loaded nanoparticles were applied together with a
second adjuvant, the immunopotentiator, CpG ODN. Moreover, all intranasally vaccinated groups showed higher interferon-c produc-
tion when compared to naı¨ve mice.
 2008 Elsevier B.V. All rights reserved.
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A safe and effective vaccine to prevent infection with
hepatitis B virus (HBV) has been available since 1982,
and is recommended by the World Health Organization
(WHO) for administration to all infants [1]. Therefore, it
is not understandable that the number of chronically0939-6411/$ - see front matter  2008 Elsevier B.V. All rights reserved.
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E-mail address: olga@ci.uc.pt (O. Borges).infected people continues to be a problem in many parts
of the World, including Asia, Africa and the western Paci-
fic region [2]. Some progress in the control of the disease in
the western Pacific area was recently reported [1] after the
inclusion of hepatitis B vaccine in every national immuni-
zation programme. Even though the price of the vaccine
had dropped significantly in the last years, there were still
some countries that could not afford these immunization
programmes. Furthermore, the control of the spread of
the disease through vaccination of infants would undoubt-
edly prevent a large number of infections among adults,
but it will take several decades to be achieved. So, the
implementation of vaccination programmes, at least for
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workers and health professionals, would certainly prevent
a large number of infections [3].
The intramuscular route of administration of the vac-
cine currently in the market, is not efficient to induce muco-
sal antibodies. The presence of antigen-specific sIgA at
mucosal surfaces has been shown to help, when the trans-
mission of the disease is through one of the mucosal routes,
which is the case of the sexual transmission of HBV. To
note that sexual transmission (either homosexual or heter-
osexual) in high-risk adults is the main mode of transmis-
sion in Europe and North America (regions of low HBV
prevalence) [2]. On the other side, the induction of mucosal
antibodies seemed to be facilitated if the antigens were
administered by a mucosal route together with an appro-
priate adjuvant. So, the development of efficient mucosal
adjuvants, which could allow an easy and inexpensive mass
vaccination and the production of more stable vaccines is
urgently required.
Among the mucosal administration routes, the nasal
mucosa is the most attractive site for the delivery of vac-
cines. Compared with the more challenging oral vaccina-
tion, the nasal route is more efficient at inducing the
secretory IgA, in particular on the cervicovaginal mucosa
[4], simultaneously with the induction of a systemic anti-
body response (reviewed in [5]). For this reason, several
attempts have been made regarding the intranasal vaccina-
tion with hepatitis B, in order to identify an effective muco-
sal adjuvant that elicits specific mucosal and systemic
hepatitis B antibodies. Adjuvants, such as recombinant
cholera toxin B subunit [6], genetically modified adenovirus
[7] expressing the hepatitis B surface antigen, attenuated
Salmonella typhimurium [8] expressing the hepatitis B
nucleocapsid, or Escherichia coli expressing the hepatitis
B nucleoprotein antigen [9], have all been shown to be effi-
cient as intranasal adjuvants. However, safety concerns
have predominantly been the cause for restricting the
development and the use of these adjuvants in clinical stud-
ies. Synthetic oligodeoxynucleotides containing immuno-
stimulatory CpG motifs (CpG ODN) are considered to
be potent immunopotentiator adjuvants. It was demon-
strated in mice that the intranasal delivery of HBsAg,
which alone has no effect, elicits good immune responses
when given in combination with CpG ODN [10–12]. More-
over, CpG is superior to cholera toxin (CT) for the induc-
tion of humoral and cell-mediated systemic immunity as
well as mucosal immune responses (IgA) at local (lung)
and distant (intestine) sites [10].
Particulate vaccine delivery systems loaded with HBsAg
have also been evaluated by the intranasal route. Some
examples already published include polymeric biodegrad-
able poly(lactide-co-glycolide) (PLGA) microparticles
[13], cationic particles (SMBVTM) [14], cationic lipid emul-
sion carrying a DNA vaccine [15] and lipid microparticles
[16].
Great attention has been devoted to the cationic biode-
gradable polysaccharide, chitosan. It is an inexpensive rawmaterial, derived from chitin the second largest abundant
natural polymer. Additionally, it has important qualities
like, low toxicity, mucoadhesive [17] and immunostimulat-
ing properties [18], hence showing enormous potential to
be used on mucosal vaccination. In fact, chitosan has been
used in nanoparticulate formulations for loading and deliv-
ering several vaccines (see Section 4). However, as far as we
know, the evaluation of chitosan based delivery systems, as
a mucosal adjuvant for hepatitis B vaccine, was never
reported. So, it is the main purpose of the present work,
to evaluate the immune response produced after i.n. vacci-
nation with HBsAg associated with the new recently char-
acterized [19,20] alginate coated chitosan nanoparticles
that was specifically designed by us for mucosal vaccina-
tion. The delivery system is composed of a chitosan core
to which the hepatitis B surface antigen (HBsAg) was
adsorbed and then coated with sodium alginate. Alginate
coating proved to modify the antigen release profile from
the chitosan nanoparticles and at the same time may pro-
tect the antigen from the enzymatic degradation during
their passage throughout mucosal surfaces. Additionally,
the HBsAg adjuvant effect of CpG ODN associated or
not with the same coated nanoparticles was investigated
as well.
2. Materials and methods
2.1. Materials
2.1.1. Polymers
Chitosan were purchased from Primex BioChemicals AS
(Avaldsnes, Norway). According to the provider’s specifi-
cations, the degree of deacetylation was 95% (titration
method) and the viscosity was 8 cP (measured in 1% solu-
tion in 1% acetic acid). A low molecular weight, pharma-
ceutical grade, sodium alginate (MANUCOL LB) was
kindly donated by ISP Technologies Inc. (Surrey, UK).
According to the provider’s specifications, the typical val-
ues for the percentage of mannuronic and guluronic acid
for Manucol LB are 61% and 39%, respectively, with an
estimated molecular weight of 18 kDa. Both polymers meet
the requisites described in the European Pharmacopoeia
for use in pharmaceutical formulations.
2.1.2. Antigen, adjuvant and reagents
The hepatitis B surface antigen (HBsAg), (subtype
ADW2) was kindly provided by GSK Biologicals (Rixens-
art, Belgium), Engerix BTM was from GlaxoSmithKline Bio-
logicals (Rixensart, Belgium), Class B CpG ODN (1826)
(50-TCC ATG ACG TTC CTG ACG TT-30) was purchased
from Coley Pharmaceutical Group (Ottawa, Canada). Con-
canavalin A (Con A), phenylmethanesulfonyl fluoride
(PMSF) and avidin peroxidase conjugate were from Sigma
Chemicals (St. Louis, USA). Certified foetal bovine serum
(FBS) and L-glutamine (200 mM) were fromGibco (Invitro-
gen Co, Paisley, Scotland, UK), 1 M Hepes buffer (0.85%
NaCl), RPMI 1640 without L-glutamine and Pen-Strep
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from Biowhitaker (Cambrex Bio Science, Verviers, Bel-
gium). [Methyl-3H] thymidine (1.0 mCi/ml) was obtained
from Amersham Biosciences (UK) and R-phycoerythrin
(PE)-conjugated hamster anti-mouse CD69, fluorescein iso-
thiocyanate (FITC)-conjugated rat anti-mouse CD4 and
FITC-conjugated rat anti-mouse CD8 were obtained from
BDBiosciences (Madrid, Spain). TheFITC-conjugated goat
anti-mouse IgM (anti-l), the anti-mouse IFN-c and biotin
rat anti-mouse IFN-c was purchased from PharMingen
(San Diego, CA, USA). The mouse IgA ELISA quantifica-
tion kit was obtained from Bethyl Laboratories (Montgom-
ery, USA). All reagents used were of analytic grade. All
solutions were prepared in ultrapure water.
2.2. Methods
2.2.1. Preparation of the coated nanoparticles
The preparation of the alginate coated chitosan nanopar-
ticles was performed according to the method previously
described [20]. Briefly, chitosanwas dissolved at a concentra-
tion of 0.25% (w/v) in diluted acetic acid solution. The for-
mation of the particles was achieved after the addition of
3.5 ml of sodium sulphate solution (10% w/v) to 200 ml of
the chitosan solution. The resulting suspension was centri-
fuged for 30 min at 3500 rpm (2800g) and the supernatant
was discarded. The particles were re-suspended in ultrapure
water and centrifuged twice. They were finally frozen in
liquid nitrogen and freeze-dried overnight using a Labconco
freeze dry system (Labconco Corporation, Kansas, USA).
The dry powder was kept frozen until further use.
The loading of the nanoparticles with HBsAg or with
CpG ODN was performed by incubating a solution of
HBsAg or the solution of CpG with a suspension of chito-
san particles in phosphate buffer at pH 7.4, under mild agi-
tation at room temperature for 120 min. In order to find
the system (nanoparticles: hepatitis B antigen) which
results in a high loading efficacy, different concentrations
of the antigen were experimented (0.5% nanoparticles:
0.1–0.0148% HBsAg). In the subsequent coating step, the
suspensions composed of 0.05% (w/v) HBsAg and 0.5%
(w/v) nanoparticles and the second with 0.05% (w/v)
CpG and 0.5% (w/v) nanoparticles were used.
Alginate coated nanoparticles were obtained by mixing
equal volumes of the loaded nanoparticles suspension
and a buffer phosphate solution of sodium alginate (1%
w/v) under magnetic stirring. The agitation was maintained
for 20 min. The suspension was then centrifuged for 10 min
at 1600 rpm and the supernatant was discarded. The parti-
cles were re-suspended in 0.262 mM CaCl2 in 50 mM
Hepes buffer solution, kept under agitation for another
10 min and immediately administered to the mice.
2.2.2. Evaluation of the loading efficacy of HBsAg and CpG
ODN in coated nanoparticles
The loading efficacy of the coated particles was calcu-
lated in an indirect way, quantifying the antigen thatremained in solution as described before [19]. After the
coating with alginate, an aliquot of the particle suspension
was centrifuged at 14,000 rpm for 15 min and the protein
concentration in the supernatant was quantified by
micro-BCA-protein assay (PIERCE, Rockford, USA)
using a microplate reader with a 570 nm filter.
For the CpG ODN the same procedure was followed
and the oligodeoxynucleotide concentration quantified by
measuring the OD of the supernatants at 260 nm. To elim-
inate background interference, the supernatant of
unloaded particles was processed by the same way. The
results refer to the nanoparticle batches used in the vacci-
nation studies.
The loading efficacy (LE) and the loading capacity (LC)
were calculated from the following equations:
LE ð%Þ ¼ ðTotal amount of HBsAg or CpG
free HBsAg or CpGÞ=Total amount
of HBsAg or CpG  100 ð1Þ
LC ðlg of HBsAg or CpG=mg chitosan
nanoparticles dry weightÞ ¼ ðTotal amount
of HBsAg or CpG free HBsAg or CpGÞ=
mg chitosan nanoparticles dry weight: ð2Þ2.2.3. Immunization studies
2.2.3.1. Animals. Seven-week-old female BALB/cAn-
NHsd mice were used (Harlan Iberia, Barcelona, Spain)
with four or six mice per group. Animals were housed
for acclimatization one week before the experiments at
the animal resource facilities of the Faculty of Phar-
macy at the University of Porto. Animal care, handling
and immunization protocols were performed and
approved in accordance with institutional ethical guide-
lines. Animals had free access to food and water and
were kept under a 12 h light/dark cycle during all the
experiment.2.2.3.2.Treatment groups.Group I suspension of alginate coated chitosan
nanoparticles loaded with 10 lg HBsAgGroup
II
s
n
uspension of alginate coated chitosan
anoparticles loaded with 10 lg HBsAg plus
10 lg of the adjuvant (CpG ODN) in solution
Group
III
s
c
uspension of the mixture of alginate coated
hitosan nanoparticles loaded with 10 lg HBsAg
and nanoparticles loaded with 10 lg CpG ODNGroup
IV
p
H
hosphate buffer saline (PBS) solution with 10 lg
BsAgGroup
V
P
O
BS solution with 10 lg HBsAg and 10 lg CpG
DNGroup
VI
untreated or negative controlGroup
VII
s
H
ubcutaneous administration of Engerix B (1 lg
BsAg) (positive control)
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was followed by two boosts with three weeks between each
immunization and the mice were sacrificed four weeks after
the last boost. To evoke an immune response a total vol-
ume of 15 ll (7.5 ll in each nostril) of the formulations
was administered. The non-anesthetized mice were main-
tained in supine position and the formulation was depos-
ited in the nasal cavity with the aid of a micropipette
with a 10 ll tip. The mice were kept in this position for
approximately another 2 min to allow optimal spreading
of the formulations on the nasal mucosa.
2.2.3.4. Sample collection. Blood samples were taken from
the orbital sinus before each boost and by cardiac puncture
at the end of the experiment. The sera were prepared by
centrifugation and stored at 20 C until analysis.
Vaginal secretions were collected at the end and four
days before the end of the experiment, by rinsing with
150 ll of a cold PBS (containing 0.1% bovine serum albu-
min (BSA)) through the vagina. The 1% BSA–PBS solution
was introduced into the vaginal tract of non-anesthetized
mice using a Gilson pipette. These 150 ll aliquots were
withdrawn and reintroduced six times.
Nasal secretions were collected just at the end of the
experiment, by washing the nasal cavity with 200 ll of cold
PBS (containing 1% BSA). The washing solution was
forced to pass throughout the trachea of the sacrificed mice
and collected from the nostrils side.
The extracts were vortexed and treated with sodium
azide and phenylmethylsulfonyl fluoride (PMSF), allowed
to stay at room temperature for at least 15 min and then
centrifuged (6000 rpm/15 min/4 C). The clear superna-
tants (containing 0.1% sodium azide, 0.1% BSA and
1 mM PMSF) were then stored at 80 C until tested by
ELISA for secretory antibody (sIgA) levels.
Faecal pellets (4–8) were collected four days before the
end of the experiment into Eppendorf tubes. The pellets
(0.2 g/ml) were suspended in PBS (containing 0.1% sodium
azide, 0.1% BSA and 1 mM PMSF), vortexed and allowed
to rest at room temperature for 1 h. Solid matter was sep-
arated by centrifugation at 14,000 rpm for 15 min. The
clear supernatants were frozen at 80 C before being used
in ELISA to determine antigen-specific and total IgA.
2.2.3.5. Enzyme-linked immunosorbent assays (ELISA) for
HBsAg specific immunoglobulins. Ninety-six-well flat-bot-
tomed microtiter plates (Nunc immunoplate maxisorb)
were previously coated with the recombinant HBsAg
(1 lg/well) in coating buffer (50 mM sodium carbonate,
pH 9.6) by overnight incubation at 4 C. The plates were
washed five times with PBS-T (PBS containing 0.05%
Tween 20) and blocked with 3% BSA in PBS-T (200 ll/
well) for 1 h at 37 C. The plates were then washed five
times with PBS-T and the serial dilutions of each serum
(100 ll/well) from the individual mice were tested in tripli-
cate, starting from a 1:100 dilution in PBS-T. The serum
was incubated for 2 h at 37 C and after washing the plateswith PBS-T, they were incubated for an additional 30 min
at 37 C with peroxidase-labelled goat anti-mouse immu-
noglobulin G and isotypes (anti-IgG1, anti-IgG2a). The
bound antibodies were revealed by adding 100 ll/well of
0.5 mg/ml of o-phenylenediamine dihydrochloride (OPD)
(Sigma, Spain) in 10 ml of citrate buffer with 10 ll of
30% H2O2. The reaction was stopped after 10 min with
50 ll of 3 M HCl to each well. The absorbance was read
out at 492 nm in an automatic ELISA reader (Easy Reader
400, SLT-LABINSTRUMENTS). Elisa titers were
expressed as mIU/ml and 1 mIU is the OD mean of the
pre-immune serum plus two times the standard deviation.
The measurement of IgA was carried out using a mouse
IgA ELISA quantification kit (Bethyl Laboratories, Mont-
gomery, Texas, USA) as described by the manufacturer. In
order to measure the sIgA levels in the gut, nasal and vag-
inal secretions, total sIgA and the specific anti-HBs sIgA
were determined in the extracts. The results are presented
as the anti-HBsAg IgA/total IgA. By this way variations
between samples related with the extraction process or sta-
bility of the sIgA were minimized.
The standard IgA was diluted to appropriate concentra-
tions in PBS with 1% BSA to create a calibration curve.
The extracts were diluted in PBS-T with 1% BSA and
added to the plates in series of 2-fold dilutions. The concen-
trations of the total and specific IgA were determined from
the calibration curve generated for each set of samples
using a four parameter logistic curve-fit generated by Sig-
maPlot software (version 8.0, SPSS Inc.).
2.2.3.6. Preparation of spleen cell suspensions. The mice
were euthanized by cervical dislocation and their spleens
were aseptically removed. Individual spleen cell suspen-
sions were prepared in a Petri dish using curved needles
and washed twice with RPMI 1640. The final suspension
was adjusted to a final concentration of 1  107 cells/ml
in a complete RPMI 1640 medium supplemented with
10% (v/v) foetal bovine serum (FBS), 1% (v/v) glutamine,
1% (v/v) Pen-Strep and 2% (v/v) 1 M Hepes buffer.
2.2.3.7. Cell population of the spleen. The cells (106) were
washed twice with cold PBS supplemented with 2% FBS
and then incubated in the dark for 30 min at 4 C with sat-
urated concentrations of FITC-conjugated rat anti-mouse
CD4 or FITC-conjugated rat anti-mouse CD8 or FITC-
conjugated goat anti-mouse IgM (anti-l). After incuba-
tion, cells were washed three times with PBS-2% FBS and
then re-suspended in 500 ll of PBS-2% FBS. To exclude
dead cells, 2.5 ll of propidium iodide (50 lg/ml) was added
just before data acquisition. At least 10,000 events were
analyzed by flow cytometric acquisition, performed in a
fluorescent activated cell sorter (FACS Calibur) (BD, Bio-
sciences, Madrid, Spain). Data were analyzed by CellQuest
software (BD, Biosciences, Madrid, Spain).
2.2.3.8. Splenocyte cell culture in the presence of the
mitogens. Using sterile 96-well flat-bottomed tissue culture
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from each mouse was plated in triplicate along with 25 ll
of a complete RPMI solution of the mitogen [Con A
(50 lg/ml), CpG ODN (50 lg/ml) plus HBsAg (16 lg/
ml), HBsAg alone (16 lg/ml) or without mitogen (con-
trol)]. Finally the volume of the well was completed to
200 ll with complete RPMI and incubated at 37 C with
95% relative humidity and in the presence of 5% CO2.
2.2.3.9. Interferon-c (IFN-c) production by splenocytes.
Spleen cell suspensions were plated with the mitogens
(see Section 2.2.3.8.) and incubated in a humidified 5%
CO2 incubator for 96 h at 37 C. The plates were centri-
fuged and the clear supernatants stored at 80 C until
analysis of the IFN-c by ELISA technique, following a
procedure described elsewhere [21].
2.2.3.10. Lymphoproliferation assay. Splenocytes were
obtained and cultured together with the mitogens in a
flat-bottomed 96-well plate as described before (see Section
2.2.3.8.). The cells were cultured for 96 h at 37 C and on
the last 8 h of incubation each well was pulsed with 1 lCi
of [methyl-3H] thymidine. These 96-well plates with the
cells were stored at 20 C until further analysis.
The cells were later thawed and harvested onto a fiber-
glass filter (filter mats, molecular devices, Skatron, Lier,
Norway) using a semiautomatic cell harvester (Scatron
Instruments, USA) and DNA thymidine incorporation
was determined by standard liquid scintillation techniques
with a Beckman LS 6500 scintillation counter (Beckman
Coulter Inc., Fullerton, USA). Thymidine incorporation
was expressed as counts per minute (cpm).
2.3. Statistical analysis
If another method is not explicitly stated, the data are
presented as means ± SEM for at least three experiments
and statistical significance was assessed using one-way
analysis of variance (ANOVA) followed by Dunnett’s post
test using the Prism 4 (GraphPad software, CA, USA).
Differences were considered significant when p < 0.05.
3. Results
3.1. Characterization of the vaccine delivery system
In a recent publication of our group [20], the develop-
ment of alginate coated chitosan nanoparticles and the
characterization of this new delivery system were reported.
Briefly, before coating with sodium alginate, chitosan
nanoparticles with a mean diameter of 643 nm (measured
by a dynamic light scattering technique) were positively
charged (+37 mV). On the other hand scanning electron
microscopy (SEM) images of the uncoated particles also
revealed the presence of small nanoparticles (around
100 nm) and the same technique also demonstrated that
the majority of the coated particles were in a range between300 and 600 nm. Coated nanoparticles are negatively
charged (35 mV) due to the contribution of the alginate.
More recently, we showed the results of the release studies,
choosing ovalbumin as a model vaccine [19]. Ovalbumin
release studies from coated and uncoated chitosan nano-
particles, performed in several buffers at different pH val-
ues, allowed us to conclude that the coating with sodium
alginate of the ovalbumin loaded chitosan nanoparticles
avoided an ovalbumin burst release observed with
uncoated chitosan nanoparticles at pH 5.5, 6.8 and 7.4
(phosphate buffer) within the first 30 min of incubation.
3.2. CpG ODN and hepatitis B antigen entrapment in coated
nanoparticles
Different ratios of hepatitis B vaccine to chitosan nano-
particles and CpG ODN to chitosan nanoparticles were
investigated (data not shown) and the systems with the
highest loading efficacy were used for further studies. It
was shown that hepatitis B antigen and CpG ODN were
efficiently associated with alginate coated chitosan nano-
particles. The loading efficacy of hepatitis B vaccine in
the coated nanoparticles was 84.1 ± 3.0% (mean ±
STDEV) and the mean of the loading capacity was
83.9 lg of HBsAg/mg of dry chitosan nanoparticles
±2.77 (STDEV). The loading efficacy of CpG was
97.0 ± 1.3% and the loading capacity was 97.0 ± 0.03 (lg
of CpG ODN/mg of dry chitosan nanoparticles).
3.3. Cellular immune responses after intranasal
administration of HBsAg loaded nanoparticles
The percentage of T- and B-lymphocytes was deter-
mined in order to examine the possible influence of the
HBsAg formulations on the cell populations of the mouse
spleen. Fig. 1A shows the results of the FACS analysis per-
formed with freshly prepared spleen cell suspensions, using
specific mAb against cell surface markers. The percentages
of CD8+ and CD4+ T-lymphocytes subpopulations in dif-
ferent groups were shown not to have been significantly dif-
ferent from the control group (p > 0.05). The group I
vaccinated with the HBsAg associated with the coated
nanoparticles was an exception and was shown to have a
significantly lower percentage (p < 0.05) of CD8+ T-cells
(0.7-fold decrease compared to the control mice), whereas
no significant difference in the ratio of CD4+/CD8+ T-cells
(Fig. 1B) was observed in the same group when compared
with the control group. A slight, but statistically significant
difference (p < 0.01) in the decrease of B cells was observed
in the groups vaccinated without nanoparticles (groups IV,
V and VII).
We also tested whether the spleen lymphocytes were sus-
ceptible to proliferation when cultured in the presence of
the antigen or the antigen plus the adjuvant. The compar-
ison between the results obtained with cells cultured with-
out mitogens (negative control of the experiment)
(Fig. 2A) and the results of cells incubated only with the
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Fig. 1. (A) Percentage of T-lymphocytes CD4+, CD8+ and B+-Lympho-
cytes in the spleens of mice from groups (I, II, III, IV, V, VI and VII) by
FACS analysis. Each bar corresponds to the group geometric mean plus the
standard error of themean. The comparison between the control group (VI)
and the different treatment groups (I, II, III, IV, V andVII) wasmadewith a
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple
comparison test (**p < 0.01 and *p < 0.05). (B) T-lymphocytes quota
between percentage of CD4+ cells and CD8+ cells from individual mouse
spleen of each group.
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presence of the antigen in the cell culture proved the ability
to induce some division of the cells. However in the con-
centration used, the stimulation appeared to be non-spe-
cific and, in general, the results shown appeared just
amplified, when compared with the results without any
stimulus. In most cases, the different groups were shown
not to be different from the control group. However, two
exceptions with a higher mean value (p < 0.01) were
observed: the group vaccinated with the antigen in solution
and the group vaccinated with a solution of the antigen in
the presence of the adjuvant (groups IV and V). Nonethe-
less, due to high variability of the individual values within
the groups, these results should not be overestimated. A
similar situation was observed for the cells cultured with
antigen in the presence of CpG ODN (Fig. 2C).Finally, Fig. 2D shows the lymphoproliferative results
observed in the presence of Con A, a classical mitogen,
which served as a positive recall antigen. In this case all
the groups vaccinated intranasally showed significantly
(p < 0.01) lower values. In addition, the group s.c. vacci-
nated with a commercial formulation showed a higher
mean value (p < 0.01) when compared to the control
(group VI).
The quantification of the interferon-c (IFN-c) in the
supernatants of the different group splenocytes, cultured
under the same conditions is shown in Fig. 3. A direct
observation of the results allowed us to conclude that the
splenocytes of all the groups vaccinated produced IFN-c.
Moreover, the statistical analysis showed that the amount
produced is significantly higher than the amount produced
by the cells from the control group in all the groups.3.4. Humoral immune response to the intranasal
administration of HBsAg nanoparticles
3.4.1. Systemic immune response
The positive control group of the experiment received a
subcutaneous injection with 1 lg of HBsAg associated with
aluminium adjuvant (commercial formulation). The high-
est concentrations of the anti-HBsAg IgG were observed
within this group (Fig. 4A). The presence of HBs specific
IgG was also observed in some mice within the groups
nasally vaccinated with the antigen and in the presence of
CpG ODN. Groups I and IV (absence of CpG ODN)
did not induce detectable anti-HBs IgG antibodies in the
plasma of any mice. Therefore the presence of a strong
mucosal adjuvant seemed to be necessary to induce a sys-
temic humoral immune response in mice vaccinated with
10 lg of the HBsAg. On the other hand, the results also
showed that within the nasally vaccinated groups the high-
est IgG titers were found in the groups where the adjuvant
was not associated with the nanoparticles (groups II and
V).
The anti-HBsAg IgG subclasses present in the responder
mice were also evaluated in order to examine the induced
Th profile as shown in Fig. 4B. In the seroconverted nasally
vaccinated mice the detected antibodies were predomi-
nantly type IgG2 (Th1–like), whereas with the commercial
formulation administered subcutaneously, the immune
response was predominantly Th2 (IgG1 > IgG2a).3.4.2. Mucosal immune response
Nasal and vaginal washings and the collection of fresh
faeces were performed at the end of the experiment in order
to detect the presence of anti-HBsAg sIgA on the mucosal
surfaces. The quantification of sIgA in the nasal washings
was possible in almost all the groups nasally vaccinated
(Fig. 5A). The exception was group IV vaccinated with a
solution of the antigen for which no specific sIgA could
be detected. In the same way, it was also not possible in
the same group (IV) to detect specific antibodies in any fae-
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ings samples (Fig. 5B).
On the other hand, the entrapment of the hepatitis B
antigen into the coated nanoparticles (group I) showed to
be valuable for the generation of specific mucosal antibod-
ies. This formulation induced the formation of anti-HBsAg
sIgA not only at the nasal mucosa (4/6) (Fig. 5A) but also
in vaginal secretions (3/6) (Fig. 5B). The application of thesuspension of the nanoparticles associated with both the
antigen and the adjuvant (group III) yielded similar results
to group I. Group II differs from group III because in this
group the CpG is not associated with the coated nanopar-
ticles. In this case not only the number of responder mice
increased (4/5 nasal secretions, 4/5 vaginal secretions) but
also the relative amount of the specific antibodies detected
was much higher (Fig. 5A and B). A similar and expected
result was obtained with the formulation in which the anti-
gen and the adjuvant were not associated with the coated
nanoparticles (group V). Therefore, anti-HBsAg sIgA in
the lung, gut, saliva, vaginal secretions and in faeces were
determined by the researchers.
Finally, the subcutaneous injection of the commercial
formulation did not produce any detectable mucosal anti-
bodies in nasal washings extracts.4. Discussion
In several publications it has been convincingly demon-
strated that the subcutaneous (sc) or the intramuscular (im)
routes of vaccine application are not effective to induce
antigen-specific mucosal antibodies. In the present work,
it was possible to confirm once more that the s.c. vaccina-
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(group VII) was unable to induce the generation of detect-
able sIgA in both, vaginal and nasal secretarial fluids. The
induction of mucosal antibodies, with few exceptions
described elsewhere [22], seems to be only feasible when a
mucosal route of vaccination was chosen and the HBs anti-
gen was associated with an appropriate adjuvant. On the
other hand, the importance of inducing mucosal antibodies
after an immunization process has been well emphasized in
the last few years [4,23,24]. This aspect is even more rele-
vant for those infections that start their deleterious effects
on the mucosal surfaces. In these cases, the infection can
be resolved before the causative agent enters in the blood.
The main protective mechanism is the generation of a local
secretory immune response, with secretory IgA (sIgA) anti-
bodies as the primary effectors molecules, but additional
humoral and cell-mediated mucosal protective mechanism
have also been identified [4,25].It is well known that one of the more important modes
of hepatitis B virus transmission is the sexual contact with
an infected person [26]. Therefore, the induction of the
anti-HBsAg sIgA at the urogenital surface would be of
great benefit. In the present work, the intranasal adminis-
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any adjuvant (group IV) was not able to induce mucosal
or systemic antibodies. Similar results were also observed
by other research groups [6,10,14]. Therefore, all the evi-
dences show that an adjuvant is required for the intranasal
route, in order to obtain a HBV protective immune
response. It has been reported that alum (insoluble alu-
minium salts), one of the few adjuvants approved by the
US Food and Drug Administration, is ineffective for
the induction of mucosal immunity [27]. Consequently,
the investigation of novel, non-toxic adjuvants for the
expression of suitable antigens at the mucosal surfaces is
necessary. In this work, the evaluation of the immune
response followed by the intranasal vaccination with the
HBs antigen associated to the alginate coated chitosan
nanoparticles is reported for the first time. This delivery
system proved to efficiently encapsulate the HBs antigen
and in preliminary studies [19] also showed the capability
for internalization by intestinal Peyer’s patches through
specialized M-cells. We did not study the uptake of the
alginate coated chitosan nanoparticles into the epithelium
of nasopharyngeal lymphoid tissue (NALT). However, it
was demonstrated by Fujimura [28,29] in an electron
microscopic study that the M-cells of human NALT are
ultrastructurally similar to those in Peyer’s patches and
colonic lymphoid follicules. On the basis of these facts,
we assumed that an identical alginate coated chitosan par-
ticle uptake in the NALT may well occur. Moreover, to
support this hypothesis, the uptake of chitosan nanoparti-
cles into the epithelium of human [30] and trimethyl-chito-
san nanoparticles into mice NALT [31] has already been
demonstrated. Equally important, in a study performed
by Tafaghodi et al. [32], alginate microspheres showed
to have a clearance rate in the human nose similar to
PLGA microspheres and lower than sephadex micro-
spheres, and were therefore considered as a suitable nasal
delivery system. The alginate coating of the chitosan
nanoparticles described here may show a similar behav-
iour as alginate particles on mucosal surfaces, at least dur-
ing the initial contact with mucosal surfaces.
In the present work, the HBV antigen associated to the
alginate coated chitosan nanoparticles was able to induce
the generation of mucosal antibodies with strong relevance
for nasal secretions. This formulation also induced to some
extent a cellular immune response; however, the highly
required systemic immune response was not induced. The
difference between these results and the ones with the solu-
tion of the antigen, proved in an indirect way the superior
capacity of the chitosan particles in retaining the antigen in
the nose cavity. On the other hand, the systemic non-
responsiveness in this group could be also explained by a
mucosally induced tolerance [5]. This is merely a hypothesis
since cellular and molecular contributions of the immuno-
competent cells present in NALT to the generation of tol-
erance are unknown [5]. On the other hand, it should be
further investigated if this kind of immune response (only
mucosal antibodies) would suffice to protect human recip-ients from a HB infection, especially against transmission
by the urogenital tract.
Anti-HBsAg IgG antibodies were detected only in the
serum of mice immunized with formulations containing
a class B CpG ODN (1826). In a comparable study per-
formed by McCluskie [33], the intranasal immunization
of mice with the same doses of the HBsAg plus the
CpG ODN in a solution, also induced the generation of
both systemic and mucosal antibodies. It has been proven
that this adjuvant is a potent immunopotentiator and can-
not be compared with an antigen delivery system. The
mechanism of the delivery systems seems to be only
related with its capacity of slow release the antigen or to
facilitate the antigen internalization into antigen-present-
ing cells (APCs) [27]. Conversely, there are strong indica-
tions that responses to CpG are dependent on the
presence of TLR9 in the cells [34–36]. After interaction
with this receptor, the activation of cell signalling path-
ways occurs, which results in a cascade of immune events
[37,38]. In the present study, the best results were found
within the groups vaccinated with the antigen associated
with the nanoparticles plus the adjuvant in solution
(group II) and in group V, vaccinated with a solution of
the antigen plus the adjuvant, being group V with the
higher titers. One of the hypotheses to explain this result
could be related with the uptake mechanism of the antigen
and the adjuvant in the NALT. In group II, the HBsAg
associated with nanoparticles may probably have been
retained in the NALT during a period that was probably
more prolonged than the time period of retention of the
adjuvant or the free antigen. This fact may cause a lower
amount of the free antigen in close proximity of the adju-
vant when compared with the situation observed in group
V, vaccinated with a solution of the antigen and the adju-
vant not associated with the nanoparticles. The proximity
between the HBV antigen and the CpG ODN has been
demonstrated to be an important condition for the inten-
sity of the antigen-specific immune response [39–41]. Some
examples were reported in the literature, e.g., the adjuvant
activity of a non-coding plasmid was demonstrated only
when the plasmid and the HBsAg were co-entrapped in
the same liposomes, but not in separate vesicles [41]. Inter-
estingly enough, we have observed the same effect: in fact
with group III, where both antigen and adjuvant were
associated with separate nanoparticles and the result
obtained was similar to the result obtained with group I
(i.e. the group without CpG ODN). The results indicated
that the association of the CpG ODN to separate chitosan
nanoparticles was not a good strategy for the intranasal
administration. Further studies are needed to evaluate if
the co-encapsulation of the antigen and the adjuvant in
the same nanoparticle would produce a better immune
response. On the other hand, the CpG ODN used in this
vaccination study is synthesized with a phosphorothioate
(PS) backbone and hence is resistant to nuclease degrada-
tion. Consequently, the use of this CpG for intranasal vac-
cination may not need protection. However, the second
414 O. Borges et al. / European Journal of Pharmaceutics and Biopharmaceutics 69 (2008) 405–416hypothetical mechanism by which the nanoparticles may
improve the efficacy of the CpG ODN is by a depot
effect, which may result in an extended period during
which, both, antigen and CpG ODN are available in
the application site, therefore increasing their probability
for being internalized by the NALT cells [35]. Therefore
in this case the encapsulation may be useful, however the
poor immunogenic response observed in group III led us
to hypothesise that the free amount of the CpG ODN
was not high enough to stimulate the immune system
to respond to the HBV antigen. Therefore, the in vivo
CpG ODN amount released from the coated nanoparti-
cles was most probably, inadequate. This phenomenon
could be associated with a strong affinity of the CpG
ODN’s to the cationic chitosan [42,43]. This hypothesis
was addressed in different studies where a poor transfec-
tion by chitosan–DNA nanoparticles was observed
[44,45] and dependent on several factors, including the
degree of deacetylation and molecular weight of the
chitosan, and the chitosan/plasmid charge ratio con-
ferred, essentially by amino groups (chitosan) and phos-
phate groups (DNA) [46,47].
Nevertheless, these results are still not fully conclusive
with regard to the advantages of the association of the
CpG ODN to nanoparticles. As referred above, theoreti-
cally, suitable nanoparticles may increase the residence
time in the NALT tissue and facilitate the internalization
of the CpG into the mucosal lymphoid tissues. This would
decrease the amount of the immunopotentiator needed for
eliciting the desirable adjuvant effect. Once inside the tar-
get tissue, the ideal delivery system should release the CpG
ODN, while most cell types have the capacity to take up
CpG ODN via endocytosis [48] or the CpG ODN inter-
nalization in cells would be facilitated by the use of
CpG associated to suitable nanoparticles.
Several studies have shown that chitosan is a biopoly-
mer with good properties to obtain a high macromolecules
(peptides, plasmid vectors, DNA and vaccines) loading
efficacy of the corresponding nanoparticles. Promising
results of intranasal vaccination using Bordetella bronchi-
septica [49], meningococcal C conjugate vaccine with
mucosal adjuvant LTK63 mutant [50], diphtheria [51,52]
and influenza antigens [53] all associated with chitosan
particles or just with chitosan powder have been demon-
strated in animal models. More recently, the nasal vacci-
nation in human volunteers by simple syringe
insufflations of Menjugate-C associated with chitosan pro-
duced geometric mean titers of serum bactericidal anti-
body comparable to parenteral immunization. More
importantly, the sIgA antibodies were detected in nasal
washings [54].
Compared with the above cited vaccines, recombinant
hepatitis B surface antigen is considered to be a weaker
antigen. Therefore, chitosan based formulations need to
be improved, in terms of a delivery system for the simulta-
neous intranasal administration of the vaccine and an
immunopotentiator yielding synergistic effects.5. Conclusion
All the intranasal formulations were able to induce the
production of the interferon-c. The values found were
comparable with the concentrations obtained in group
s.c. vaccinated with the commercial formulation. Again
similar to the behaviour found for the commercial formu-
lation was the lower percentage of B-lymphocytes
observed in groups i.n. vaccinated with formulations with-
out nanoparticles.
The association of the HBsAg with alginate coated
chitosan nanoparticles, administered nasally to mice, gave
rise to humoral mucosal immune responses, which were
not induced by the HBsAg alone. The generation of sys-
temic antibodies, predominantly Th1-type antibodies, was
observed when the HBV antigen entrapped in the particles
was administered simultaneously with the adjuvant, CpG
ODN, in solution. Future work will focus in the improve-
ment of the chitosan nanoparticles in order to better con-
trol the in vivo CpG ODN release from the particles and
the co-entrapment of the antigen and the adjuvant, in order
to elicit not only mucosal antibodies but also, if possible,
systemic humoral immune response.Acknowledgements
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